GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » Beneish M-Score

SomaLogic (SomaLogic) Beneish M-Score : -2.38 (As of Apr. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is SomaLogic Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.38 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for SomaLogic's Beneish M-Score or its related term are showing as below:

SLGC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.38   Med: -0.51   Max: 1.13
Current: -2.38

During the past 3 years, the highest Beneish M-Score of SomaLogic was 1.13. The lowest was -2.38. And the median was -0.51.


SomaLogic Beneish M-Score Historical Data

The historical data trend for SomaLogic's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic Beneish M-Score Chart

SomaLogic Annual Data
Trend Dec20 Dec21 Dec22
Beneish M-Score
- - 0.45

SomaLogic Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 0.45 -1.39 -0.51 -2.38

Competitive Comparison of SomaLogic's Beneish M-Score

For the Health Information Services subindustry, SomaLogic's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SomaLogic's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where SomaLogic's Beneish M-Score falls into.



SomaLogic Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of SomaLogic for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0312+0.528 * 1.4548+0.404 * 1.3654+0.892 * 0.8025+0.115 * 0.5319
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0882+4.679 * -0.02524-0.327 * 0.8718
=-2.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $20.73 Mil.
Revenue was 22.048 + 20.468 + 20.379 + 18.829 = $81.72 Mil.
Gross Profit was 10.413 + 9.293 + 8.063 + 5.864 = $33.63 Mil.
Total Current Assets was $494.11 Mil.
Total Assets was $565.05 Mil.
Property, Plant and Equipment(Net PPE) was $18.17 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.23 Mil.
Selling, General, & Admin. Expense(SGA) was $128.24 Mil.
Total Current Liabilities was $27.78 Mil.
Long-Term Debt & Capital Lease Obligation was $2.76 Mil.
Net Income was -22.157 + -24.772 + -34.202 + -49.251 = $-130.38 Mil.
Non Operating Income was -3.841 + 0.527 + 1.068 + 3.381 = $1.14 Mil.
Cash Flow from Operations was -21.365 + -26.237 + -43.045 + -26.608 = $-117.26 Mil.
Total Receivables was $25.05 Mil.
Revenue was 41.713 + 14.144 + 22.98 + 22.994 = $101.83 Mil.
Gross Profit was 30.043 + 7.067 + 11.328 + 12.531 = $60.97 Mil.
Total Current Assets was $621.26 Mil.
Total Assets was $688.24 Mil.
Property, Plant and Equipment(Net PPE) was $19.91 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.55 Mil.
Selling, General, & Admin. Expense(SGA) was $146.84 Mil.
Total Current Liabilities was $42.68 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(20.73 / 81.724) / (25.05 / 101.831)
=0.253659 / 0.245996
=1.0312

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(60.969 / 101.831) / (33.633 / 81.724)
=0.598727 / 0.411544
=1.4548

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (494.105 + 18.172) / 565.048) / (1 - (621.26 + 19.91) / 688.244)
=0.093392 / 0.068397
=1.3654

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=81.724 / 101.831
=0.8025

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.55 / (3.55 + 19.91)) / (7.225 / (7.225 + 18.172))
=0.151321 / 0.284482
=0.5319

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(128.237 / 81.724) / (146.835 / 101.831)
=1.569147 / 1.441948
=1.0882

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.763 + 27.781) / 565.048) / ((0 + 42.675) / 688.244)
=0.054056 / 0.062006
=0.8718

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-130.382 - 1.135 - -117.255) / 565.048
=-0.02524

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

SomaLogic has a M-score of -2.38 suggests that the company is unlikely to be a manipulator.


SomaLogic Beneish M-Score Related Terms

Thank you for viewing the detailed overview of SomaLogic's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


SomaLogic (SomaLogic) Business Description

Traded in Other Exchanges
N/A
Address
2945 Wilderness Place, Boulder, CO, USA, 80301
SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.
Executives
Alison Marie Roelke officer: Chief People Officer 900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich officer: Interim CEO C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez officer: General Counsel 6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs director C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey director 8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman officer: Chief Financial Officer C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post director 998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis director 13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake director C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi director